Topic: vaccine development
Amgen pays $2.7 billion for a 20.5% stake in BeiGene. AstraZeneca tightens its ties to China as China approves a controversial Alzheimer's drug.
WuXi Biologics expects to have a plant in Europe complete in 2021 as a capacity race plays out among Asia’s rapidly growing biologics CDMOs.
CureVac is working on a printer to quickly create mRNA vaccine candidates against known pathogens and unknown diseases.
Themis' win comes after the FDA granted the same designation to chikungunya candidates from PaxVax and Valneva.
Merck's 15-strain pneumococcal vaccine got an FDA breakthrough tag for children, months after Pfizer's 20-valent shot won one in adults.
Pfizer's Staphylococcus aureus vaccine candidate was among a group of pipeline shots the company hoped could propel growth beyond Prevnar 13.
Takeda's dengue shot met its goal in a pivotal phase 3 study that covered eight countries and more than 20,000 participants.
While Valneva already markets two vaccines, the company is open to building its commercial business through small acquisitions, its CEO said.
Here is some other vaccine news of note for the week.
To make sense of Sanofi's Dengvaxia experiences, look no further than the old adage: Learn from your mistakes.